CARESIDE, a leading animal pharmaceutical company headed by Chief Executive Officer (CEO) Yoo Young-guk, announced on Wednesday that its next-generation swine vaccine technology has been certified as a New Excellent Technology (NET) by the Ministry of Agriculture, Food and Rural Affairs.
On January 7, the Agricultural Technology Planning and Evaluation Institute, a division of the Ministry, officially recognized CARESIDE’s innovative multi-immunization vaccine technology. This groundbreaking approach simultaneously incorporates virus-like particles (VLP)-based PCV2 mixed antigens, Mycoplasma p65, and two types of inactivated bacteria. The technology has been designated as a NET for the latter half of 2025.
The newly certified technology is a cornerstone of CARESIDE’s flagship product, Xenovax PCM4. This cutting-edge multi-immunization vaccine offers simultaneous protection against Porcine Respiratory Disease Complex (PRDC), primarily caused by Porcine Circovirus type 2 (PCV2) and Mycoplasma. The certification will remain valid for two years, expiring in January 2028.
The technology has garnered recognition for its advanced features, including the incorporation of the prevalent PCV2d genotype, the application of T_BLS antigens that boost cellular immune responses, and the addition of Mycoplasma hyosynoviae, a pathogen of increasing concern.
During the rigorous evaluation process, the technology’s economic and industrial impact received high marks. By employing a multi-antigen expression system for high-efficiency production, the technology not only reduces costs but also combines six antigens into a single vaccine. This innovation significantly decreases the number of required vaccinations, thereby reducing labor demands for farmers.
Furthermore, the technology maximizes immune persistence through an optimized adjuvant system that activates antigen-presenting cells and promotes sustained immune stimulation.
CEO Yoo commented that this NET certification underscores that Xenovax PCM4 isn’t just another new product, but a revolutionary technology poised to set global standards. By bringing this world-first product to market, it aims to boost the income of domestic swine farmers and cement the position as a leader in the global animal vaccine industry.